Sareum Holdings (SAR)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

 21.00p
   
  • Change Today:
      0.000p
  • 52 Week High: 27.50
  • 52 Week Low: 12.00
  • Currency: UK Pounds
  • Shares Issued: 138.57m
  • Volume: 30,778
  • Market Cap: £29.10m
  • RiskGrade: 594

Latest ShareCast News

Sareum reports progress across pipeline

By Josh White

Date: Tuesday 09 Dec 2025

(Sharecast News) - Sareum updated investors on progress across its pipeline ahead of its annual general meeting on Tuesday, highlighting continued advances in its lead autoimmune candidate SDC-1801 and strengthening commercial positioning for its cancer assets SDC-1802 and SRA737.

Sareum halts toxicology study after control-group safety findings

By Iain Gilbert

Date: Friday 10 Oct 2025

(Sharecast News) - Clinical-stage biotechnology firm Sareum said on Friday that it has discontinued its 16-week pre-clinical toxicology study for autoimmune and cancer candidate SDC-1801 after safety issues were flagged by a third-party provider.

Sareum starts toxicology studies for lead inhibitor

By Josh White

Date: Thursday 29 May 2025

(Sharecast News) - Sareum announced the start of a programme of toxicology studies on Thursday, for its lead TYK2/JAK1 inhibitor - SDC-1801 - marking a key step toward phase two clinical development.

Sareum shares drop on product licence termination 31-Dec-2024 ShareCast
Sareum shares rise on China patent allowance 16-Sep-2024 ShareCast
Sareum announces positive results from kinase in... 01-Jul-2024 ShareCast
Sareum allowed European patent for primary kinas... 15-Mar-2024 ShareCast
Sareum reports positive progress in psoriasis pr... 15-Feb-2024 ShareCast
Sareum shares jump on cancer drug licensing deal 02-Jan-2024 ShareCast
Sareum secures Japan patent for kinase inhibitor... 03-Nov-2023 ShareCast
Sareum losses widen as clinical trials continue 09-Oct-2023 ShareCast
Director dealings: Blackbird, Sareum insiders pi... 06-Sep-2023 ShareCast
Sareum granted new patents in China, US 26-Jun-2023 ShareCast
Sareum gets approval for phase one psoriasis stu... 05-May-2023 ShareCast
Sareum looks at options as GSK division returns ... 06-Mar-2023 ShareCast
Sareum confident despite recent setbacks 16-Dec-2022 ShareCast
Sareum progresses Covid-19 and autoimmune treatm... 16-Mar-2022 ShareCast
Sareum expects FY losses to widen on higher R&D ... 19-Aug-2021 ShareCast
Sareum positive on SRA737 outlook after Sierra c... 06-Aug-2021 ShareCast
Sareum releases 'encouraging' results from Covid... 01-Jul-2021 ShareCast
 

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

Sareum Holdings Market Data

Currency UK Pounds
Share Price 21.00p
Change Today 0.000p
% Change 0.00 %
52 Week High 27.50
52 Week Low 12.00
Volume 30,778
Shares Issued 138.57m
Market Cap £29.10m
RiskGrade 594

Sareum Holdings Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
46.86% below the market average46.86% below the market average46.86% below the market average46.86% below the market average46.86% below the market average
2.44% below the sector average2.44% below the sector average2.44% below the sector average2.44% below the sector average2.44% below the sector average
Price Trend
27.48% below the market average27.48% below the market average27.48% below the market average27.48% below the market average27.48% below the market average
9.09% above the sector average9.09% above the sector average9.09% above the sector average9.09% above the sector average9.09% above the sector average
Income Not Available
Growth Not Available

Sareum Holdings Dividends

No dividends found

Trades for 15-May-2026

Time Volume / Share Price
14:57 868 @ 21.40p
11:07 2,045 @ 22.00p
10:23 9,045 @ 21.35p
10:03 233 @ 21.40p
09:27 12,045 @ 21.30p

Sareum Holdings Key Personnel

COO Timothy J Mitchell

Top of Page